ALS start-up funded by BII

ALS start-up funded by BII

The therapeutics start-up 2N Pharma is one of the five new companies in BioInnovation Institute’s Creation House program. The start-up is developing an alternative to today’s treatment of amyotrophic lateral sclerosis (ALS) and is building its case on 10...
Thomas Brimert, PhD

Thomas Brimert, PhD

Received a PhD in organic chemistry from the Royal Institute of Technology in Stockholm. During his 11 years at AstraZeneca R&D Lund, he gained considerable medicinal chemistry experience. He has contributed to successfully delivered clinical candidates in kinase,...
Michael Sloth Trabjerg, MD

Michael Sloth Trabjerg, MD

Dr. Trabjerg is a Medical Doctor currently working as a PhD-fellow at the Laboratory of Metabolism Modifying Medicine, Aalborg University. He has a special interest in autoimmune and neurodegenerative brain diseases with focus on lipid metabolism and mitochondrial...